808768-94-7

Upstream product

• 64-17-5 ethanol 
• 808768-95-8 (3-{2-[(chloroacetyl)amino]-2-methylpropyl}phenyl)acetic acid 
• 1313220-75-5 C₁₂H₁₇NO₂ 
• 808768-96-9 2-[3-(2-hydroxy-2-methylpropyl)phenyl]acetic acid 
• 921598-15-4 ethyl 2-{3-[2-(2-chloroacetamido)-2-methylpropyl]phenyl}acetate 
• 861448-90-0 ethyl 2-[3-(2-amino-2-methylpropyl)phenyl]acetate hydrogen (2R,3R)-2,3-bis[(4-methylbenzoyl)oxy]succinate 

Downstream Products

• 861448-90-0 ethyl 2-[3-(2-amino-2-methylpropyl)phenyl]acetate hydrogen (2R,3R)-2,3-bis[(4-methylbenzoyl)oxy]succinate 
• 861448-92-2 ethyl (R)-2-(3-{2-[2-hydroxy-2-(4-benzyloxy-3-methanesulfonamidophenyl)ethylamino]-2-methylpropyl}phenyl)acetate 
• 861448-93-3 [3-(2-{[(2R)-2-{4-(benzyloxy)-3-[(methylsulfonyl)amino]phenyl}-2-hydroxyethyl]amino}-2-methylpropyl)phenyl]acetic acid 
• 921598-16-5 ethyl [3-(2-tert-butoxycarbonylamino-2-methylpropyl)phenyl]acetate 
• 861448-91-1 ethyl (3-{2-[((2R)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-{4-benzyloxy-3-[(methylsulfonyl)amino]phenyl}ethyl)amino]-2-methylpropyl}phenyl)acetate 

Relevant academic research and scientific papers

Enzymatic desymmetrization route to ethyl [3-(2-amino-2-methylpropyl) phenyl]acetate

An efficient process to ethyl [3-(2-amino-2-methylpropyl)phenyl]acetate 6 has been developed. Key steps include a novel enzymatic desymmetrization of diester 2 and a Ritter reaction between alcohol 4 and chloroacetonitrile, followed by chemoselective deprotection with thiourea.

Development of an enabling route to PF-00610355: A novel inhaled β2-adrenoreceptor agonist

The initial route used to prepare PF-00610355 (8) for early clinical development is described. Through careful choice of solvent, an efficient, telescoped route to carboxylic acid 23 was developed, affording this late-stage intermediate in 80% yield over 4 steps. Deprotection of 23 to give sodium salt 24a and coupling with amine 6·HCl afforded the desired API. Effective synthetic routes to two of the starting materials, chiral bromide 1 and amine 6, are also described.

PROCESS FOR THE PREPARATION OF SULFONAMIDE DERIVATIVES

The invention relates to a process for the preparation of compounds of formula (I) wherein Q1 is a group selected from formulae (II and (III) and a group *-NR6 -Q2-A or, if appropriate, their pharmaceutically acceptable sa

Phenylethanolamine derivatives as beta-2 agonists

The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in

Sulfonamide derivatives for the treatment of diseases

The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in

Sulfonamide derivatives for the treatment of diseases

The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

2-(6-AMINO-PYRIDIN-3-YL)-2-HYDROXYETHYLAMINE DERIVATIVES AS BETA 2-ADRENOCEPTORS AGONISTS

The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in